(Q35773852)

10 August 2017

1 reference

title

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow (English)

1 reference

10 August 2017

Janet E Dancey

1 reference

10 August 2017

language of work or name

1 reference

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

411-415

1 reference

Cigarette smoking and histologic type of lung cancer in men.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

The EGF receptor: a nexus for trafficking and signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Nobel lecture. Epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Filter cigarette smoking and lung cancer risk; a hospital-based case--control study in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Signal transduction. Autoinhibition control

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2804%2900122-9

7 January 2021

10.1016/S1535-6108(04)00122-9

Identifiers

DOI

1 reference

release_wf7sdhqdyjfy3at2l46snnfhyy

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wf7sdhqdyjfy3at2l46snnfhyy

24 November 2022

mapped directly with Wikidata item

1 reference